• Roivant’s net loss attributable to shareholders widened 69% year over year to $191.62 million for the second quarter ended September 30, 2026.
• Revenue rose to $35.12 million, including $31 million from LISRAYA’s first five weeks of launch.
• Cash, cash equivalents and marketable securities totaled $4.2 billion at September 30, supporting a cash runway into profitability.
• IMVT-1402’s 600-mg dose met the rheumatoid arthritis trial’s primary endpoint; FDA discussions are planned later this year.
• Brepocitinib met primary and all key secondary endpoints in two Phase 3 uveitis trials; a supplemental application is expected in first-half 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872953) on November 09, 2026, and is solely responsible for the information contained therein.